A recent study suggests that people who discontinue new slimming jabs like Wegovy and Mounjaro can put back on lost weight much more quickly than those who end conventional lifestyle regimens.
Findings released in a prominent health publication points out that while overweight individuals frequently drop about a fifth of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People purchasing these treatments need to be informed of the danger of rapid rebound weight gain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to pre-treatment weight in about a year and a half.
Comparing Approaches
The study, which reviewed dozens of studies involving over 9,000 of patients, contrasted the effects of these new drugs with other pills.
The team emphasize that people who lose weight through diet and exercise usually experience a more gradual creep back—around 100 grams monthly—once they finish.
The Reason for the Rapid Rebound
Doctors suggest the mechanism of the drugs is key to understanding the accelerated weight return.
The injections mimic a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels far above than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement leads to appetite is unsuppressed, making excessive eating much more probable."
An Ongoing Condition?
Medical guidelines suggest the injections for people with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians say that, due to the significant potential of relapse, the therapy is often life-long.
This perspective is supported by drug manufacturers, who say that the findings "highlight the persistent nature of obesity," akin to managing conditions like hypertension.
Patient Accounts
Users who have stopped the medication report a intense return of appetite.
"It felt as if a switch that goes on and I was suddenly ravenous," said an individual.
This challenge is compounded if patients have not established permanent dietary or behavioural changes during therapy.
Growing Use
Survey data show that millions of people in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Adoption is higher among females compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, researchers caution that while these medications are potent tools for weight loss, they are not a standalone cure and lasting health benefits hinges on integrated behavioural management.
